Implied Volatility Surging for Intellia (NTLA) Stock Options 02/07/20-7:54AM EST Zacks. More Zacks News for NTLA. Other News for NTLA Stocks That Hit 52-Week Highs On Tuesday 05/19/20-9:45AM EST NTLA: Intellia Therapeutics Inc - Earnings Announcements. Stay up to date with lastest Earnings Announcements for Intellia Therapeutics Inc from Zacks Investment Research Implied Volatility Surging for Intellia (NTLA) Stock Options by Zacks Equity Research Published on February 07,2020 Investors need to pay close attention to Intellia (NTLA) stock based on the NTLA: Intellia Therapeutics Inc - Full Company Report. Get the latest Full Company Report for Intellia Therapeutics Inc from Zacks Investment Research NTLA: Intellia Therapeutics Inc broker recommendations. Get the latest broker recommendations from Zacks Investment Research. Intellia Therapeutics Inc (NASDAQ:NTLA) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.63) EPS for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.24.
Implied Volatility Surging for Intellia (NTLA) Stock Options by Zacks Equity Research Published on February 07,2020 Investors need to pay close attention to Intellia (NTLA) stock based on the
Zacks Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2% Intellia Therapeutics (NTLA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes. View Intellia Therapeutics Inc NTLA investment & stock information. Get the latest Intellia Therapeutics Inc NTLA detailed stock quotes, stock data, Real-Time Inc. (NTLA)? Use the Zacks Rank and Style Scores to find out is NTLA is right for your portfolio. View All Zacks #1 Ranked Stocks. Trades from $1. The Zacks Market Cap is a widely used stock evaluation measure. Find the latest Market Cap for Intellia Therapeutics Inc (NTLA) 6 days ago Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2%. Zacks Equity Research June 04, 2020. AGEN NTLA. Trades from 30 Apr 2020 What You Should Know. Zacks Equity Research April 30, 2020. NTLA. Trades from $1.
Intellia Therapeutics Inc. company facts, information and stock details by MarketWatch. View ntla business summary and other industry information.
6 days ago AGEN, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. These Stocks Are Poised to NTLA Intellia Therapeutics, Inc. daily Stock Chart Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2%. Zacks. Jun-04-20 01:55AM. Edited Transcript Podcast by Zacks Investment Research. (0:45) - Finding Zacks #1 Rank Value Stocks (7:00) - Tracey's Top Stock Picks (21:25) - Episode Roundup: AMKR, Daily alert with stock picks that combine momentum with high Zacks ranking. When I last wrote, it was to share with you some stocks that the folks at Zacks think $2k and purchased several of his recommended stocks - EDIT, CRSP, NTLA, . NTLA, Intellia Therapeutics - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Zacks Equity Research 05/07/2020 03:15 AM ET Listen to episodes of Zacks Market Edge on Podbay, the fastest and easiest way (0:45) - Finding Zacks #1 Rank Value Stocks (7:00) - Tracey's Top Stock Picks
Zacks Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2% Intellia Therapeutics (NTLA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
NTLA Intellia Therapeutics, Inc. daily Stock Chart Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2%. Zacks. Jun-04-20 01:55AM. Edited Transcript Podcast by Zacks Investment Research. (0:45) - Finding Zacks #1 Rank Value Stocks (7:00) - Tracey's Top Stock Picks (21:25) - Episode Roundup: AMKR,
View Intellia Therapeutics Inc NTLA investment & stock information. Get the latest Intellia Therapeutics Inc NTLA detailed stock quotes, stock data, Real-Time
NTLA: Intellia Therapeutics Inc - Full Company Report. Get the latest Full Company Report for Intellia Therapeutics Inc from Zacks Investment Research NTLA: Intellia Therapeutics Inc broker recommendations. Get the latest broker recommendations from Zacks Investment Research.